Autolus Therapeutics
Focused on the development of precisely targeted, controlled & highly active T cell therapies for cancer
763 employees · est. 2014 · London, United Kingdom
Kyverna Therapeutics
Harnessing the power of cell therapy in autoimmune disease.
160 employees · est. 2018 · Emeryville, United States
Autolus Therapeutics is the older company (2014 vs 2018); Autolus Therapeutics is the larger of the two.
1 signal in the last 90 days
Side-by-Side Comparison
| Metric | Autolus Therapeutics | Kyverna Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2014 older | 2018 |
| Headquarters | ||
| Headquarters | London, United Kingdom | Emeryville, United States |
| Employees | ||
| Employees | 763 larger | 160 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Pharmaceutical | Not tracked yet |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | IPO |
| Total Funding | ||
| Total Funding | $1.07B | $489.00M |
| Funding Rounds | ||
| Funding Rounds | 10 | 6 |
| Services | ||
| Services | Development of autologous T cell therapies, Advanced cell programming, Manufacturing of T cells, Clinical trial management, Pipeline products for cancer and autoimmune diseases | Development of CAR T-cell therapies for autoimmune diseases, Clinical trials management, Patient-centric therapeutic solutions, Next-generation cell therapy pipeline |
| Target Customers | ||
| Target Customers | Patients with cancer and autoimmune diseases, Healthcare professionals, Investors interested in biotech innovations, Research institutions | Patients with autoimmune diseases, Healthcare providers specializing in rheumatology and neurology, Clinical research organizations |
| Taxonomy | ||
| Taxonomy | CAR T Cell Therapy, T Cell Programming, Cancer Treatment, Autologous T Cell Therapies, Next-generation Therapies, Obe-cel (obecabtagene Autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, AUTO8, Autoimmune Disease Treatment, Biopharmaceuticals, Therapeutic Pipeline | Cell Therapy, Biopharmaceuticals, Autoimmune Diseases, CAR T-cell Therapy, CD19-targeting, Neuroimmunology, Stiff Person Syndrome, Generalized Myasthenia Gravis, Multiple Sclerosis, Rheumatoid Arthritis, T-cell Engineering, Synthetic Biology, Curative Treatments, B-cell-driven Diseases, Autologous Therapies |
| Website | ||
| Website | autolus.com | kyvernatx.com |
About Autolus Therapeutics
Autolus Therapeutics, founded in 2014, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. Based in the United Kingdom, the company is renowned for its innovative approach towards cancer treatment, with a clear focus on developing precisely targeted and highly con...
About Kyverna Therapeutics
Kyverna Therapeutics, founded in 2018, is a United States-based clinical-stage biopharmaceutical company that aims to revolutionize treatment for autoimmune diseases by leveraging cell therapy. Their slogan, "Harnessing the power of cell therapy in autoimmune disease," highlights their focus on prov...
We will tell you when either one moves
BounceWatch watches Autolus Therapeutics and Kyverna Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Autolus Therapeutics and Kyverna Therapeutics — by email.
Frequently Asked Questions
Compare Autolus Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Autolus Therapeutics on 1 Apr 2026, and Kyverna Therapeutics on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
